Vicat: Nine-Month 2023 Sales
 L’ISLE D’ABEAU, France--(BUSINESS WIRE)--Regulatory News: Vicat (Paris:VCT): â–¼ Strong growth in third-quarter sales (up…
3 years ago
Wire Stories
DigitalBridge to Participate in Upcoming Investor and Industry Conferences in November 2023
BOCA RATON, Fla.--(BUSINESS WIRE)--DigitalBridge Group, Inc. (“DigitalBridge†or the “Companyâ€) (NYSE: DBRG), a leading global…
3 years ago
Renesas Unveils Processor Roadmap for Next-Gen Automotive SoCs and MCUs
Future Offerings to Include R-Car SoCs with Advanced In-Package Chiplet Integration Technology and Arm-Based Automotive…
3 years ago
Edgecore Wi-Fi Partners with Hualien Tzu Chi Hospital to Pioneer Smart Healthcare
HSINCHU, Taiwan--(BUSINESS WIRE)--Edgecore Networks, a leading provider of traditional and open network solutions for enterprises,…
3 years ago
H2O.ai Kicks Off Inaugural Open Source GenAI World Event in San Francisco with the Winning Kaggle LLM Team and SF’s Largest Gathering of AI Grandmasters
SF’s largest gathering of Kaggle Grandmasters brings in 1000+ GenAI users to the biggest GenAI…
3 years ago
Mary Kay Ash Foundationâ„ Celebrates Five Years Shaping the Future of Cancer Research in Partnership With UT Southwestern Medical Center
DALLAS--(BUSINESS WIRE)--The Mary Kay Ash Foundationâ„ , a decades-long leader and advocate for finding cures for…
3 years ago
Saudi Fund for Development Inaugurates Vocational College and Attends High-Level Event in Vietnam
HANOI, Vietnam--(BUSINESS WIRE)--The Saudi Fund for Development (SFD) Chief Executive Officer, H.E. Sultan Al-Marshad, officially…
3 years ago
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc†or the “Companyâ€), a biopharmaceutical company…
3 years ago
Parse Biosciences Extends Global Reach with India-based Spinco Biotech Partnership
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today…
3 years ago
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With…
3 years ago